Cross Country Healthcare Acquisition Faces Investor Doubts Amid Regulatory Delays

Cross Country Healthcare finds itself navigating turbulent waters as its proposed acquisition by Aya Healthcare faces mounting skepticism from investors. The stock’s current trading pattern reflects deep market concerns about the deal’s completion, with shares trading at a substantial 42% discount to the proposed cash offer price. This significant gap underscores widespread doubt about the transaction’s ultimate success.

Financial Performance Adds to Uncertainty

The company’s third quarter 2025 results fell short of market expectations on multiple fronts, compounding the acquisition-related concerns. Both revenue and earnings missed analyst projections, prompting management to take the unusual step of canceling the earnings presentation and withdrawing financial guidance—officially attributed to the pending transaction.

Key financial metrics reveal a complex picture:
* Revenue growth registered at -20.60%
* Earnings per share came in at -0.49
* Return on equity stood at -3.77%
* Free cash flow remained strong at $57.34 million
* The price-to-earnings ratio of 66.91 indicates elevated market expectations

Regulatory Timeline Extends Acquisition Uncertainty

The merger agreement has been automatically extended through December 3, 2025, signaling ongoing regulatory complexities. Both companies have submitted comprehensive documentation to the Federal Trade Commission, but the extended timeline suggests a challenging approval process ahead.

Should investors sell immediately? Or is it worth buying Cross Country Healthcare?

The current stock price of $11.54 sits far below the $18.61 per share cash offer from Aya Healthcare. This dramatic spread highlights investor apprehension about whether regulatory hurdles can be cleared.

Technical Indicators Signal Bearish Momentum

From a technical analysis perspective, Cross Country Healthcare shares show concerning patterns. The stock recently declined by 1.70% and has lost more than 11% over the past two weeks. More alarmingly, the shares are trading below key technical levels that typically provide support.

Technical analysis reveals:
* Price below both the 50-day moving average ($12.72) and 200-day moving average ($13.86)
* Relative Strength Index at an extreme 91.47, indicating overbought conditions
* Moving averages generating sell signals across multiple timeframes

The critical question for investors remains whether the acquisition will ultimately proceed and provide the anticipated upside, or if regulatory rejection could trigger further declines. The extended December deadline now serves as the next potential catalyst for resolution.